|drug3677||Vitamin D 1000 IU Wiki||1.00|
|D058345||Asymptomatic Infections NIH||0.71|
|D014808||Vitamin D Deficiency NIH||0.35|
|D012141||Respiratory Tract Infections NIH||0.18|
There is one clinical trial.
This research study will evaluate the association of Androgen Receptor (AR) gene expression and COVID-19 disease severity and mortality. The research procedure involves collection of a single saliva sample which will be mailed to the participants by the study team. This saliva will be used in a COVID-19 Androgen Sensitivity Test (CoVAST) which will detect AR gene expression. Eligible participants are males, at least 18 years or older, and have tested positive for COVID-19.
Description: Number of subjects deceased at or before 28 daysMeasure: Number of patients deceased Time: 28 days
Description: Number of patients discharged at or before 14 daysMeasure: Number of patients discharged Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports